{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:48:15Z","timestamp":1757623695074,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007271","name":"Health Science Center, University of Tennessee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006537","name":"Vanderbilt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.rcsop.2022.100163","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T04:42:09Z","timestamp":1659156129000},"page":"100163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA)"],"prefix":"10.1016","volume":"7","author":[{"given":"Karen B.","family":"Farris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Cadwallader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Farley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Gatwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Mackler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Gatwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"SEER Cancer Statistics Review, 1975\u20132015","author":"Noone","key":"10.1016\/j.rcsop.2022.100163_bb0005"},{"key":"10.1016\/j.rcsop.2022.100163_bb0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","article-title":"Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States","volume":"32","author":"Song","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rcsop.2022.100163_bb0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/1078155219875206","article-title":"Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions","volume":"26","author":"Dashputre","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.rcsop.2022.100163_bb0020","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","article-title":"A systematic review of adherence to oral antineoplastic therapies","volume":"21","author":"Greer","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.rcsop.2022.100163_bb0025","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2217\/fon-2017-0727","article-title":"Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat","volume":"14","author":"Chari","year":"2018","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.rcsop.2022.100163_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214446","article-title":"Adherence to immunomodulatory drugs in patients with multiple myeloma","volume":"14","author":"Cransac","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.rcsop.2022.100163_bb0035","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1177\/1078155219827637","article-title":"Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees","volume":"25","author":"Patel","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.rcsop.2022.100163_bb0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.rcsop.2022.100163_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1185\/03007995.2014.991440","article-title":"Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs","volume":"31","author":"Ward","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rcsop.2022.100163_bb0050","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.rcsop.2022.100163_bb0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/phar.1399","article-title":"Improving adherence to oral cancer therapy in clinical practice","volume":"34","author":"McCue","year":"2014","journal-title":"Pharmacother"},{"key":"10.1016\/j.rcsop.2022.100163_bb0060","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1200\/JOP.17.00039","article-title":"Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led Oral chemotherapy management program","volume":"14","author":"Muluneh","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.rcsop.2022.100163_bb0065","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.rcsop.2022.100163_bb0070","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s12032-010-9542-z","article-title":"Management of disease- and treatment-related complications in patients with multiple myeloma","volume":"27","author":"Gay","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.rcsop.2022.100163_bb0075","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.rcsop.2022.100163_bb0080","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol"},{"issue":"15 suppl","key":"10.1016\/j.rcsop.2022.100163_bb0085","article-title":"Cancer survivors with multiple chronic conditions: a rising challenge \u2013 trend analysis from National Health Interview Survey","volume":"38","author":"Jiang","year":"2020"},{"key":"10.1016\/j.rcsop.2022.100163_bb0090","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1200\/JOP.2016.018390","article-title":"Implementing a method for evaluating patient-reported outcomes associated with oral oncolytic therapy","volume":"13","author":"Mackler","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.rcsop.2022.100163_bb0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton symptom assessment system 25 years later: past, present and future developments","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.rcsop.2022.100163_bb0100","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/archinternmed.2011.399","article-title":"Impact of pharmacist care in the management of cardiovascular disease risk factors","volume":"171","author":"Santschi","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rcsop.2022.100163_bb0105","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.20.03088","article-title":"The randomized AMBORA trial: impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents","volume":"39","author":"D\u00fcrr","year":"2021","journal-title":"J Clin Oncol"},{"author":"Fact Sheet Summary of 2019 MTM Programs","key":"10.1016\/j.rcsop.2022.100163_bb0110"},{"key":"10.1016\/j.rcsop.2022.100163_bb0115","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2017.73.1307","article-title":"Patient preferences for primary care provider roles in breast cancer survivorship care","volume":"35","author":"Wallner","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Supp 2","key":"10.1016\/j.rcsop.2022.100163_bb0120","first-page":"S265","article-title":"The role of primary care physicians in advance cancer care: perspectives of older patients and their oncologists","volume":"57","author":"O\u2019Toole","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.rcsop.2022.100163_bb0125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/pon.1996","article-title":"The Edmonton symptom assessment system, a proposed tool for distress screening in cancer patients: development and refinement","volume":"21","author":"Watanabe","year":"2012","journal-title":"Psychooncology"},{"key":"10.1016\/j.rcsop.2022.100163_bb0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10461-012-0326-7","article-title":"Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV","volume":"17","author":"Feldman","year":"2013","journal-title":"AIDS Behav"},{"key":"10.1016\/j.rcsop.2022.100163_bb0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10461-007-9261-4","article-title":"Optimal recall period and response task for self-reported HIV medication adherence","volume":"12","author":"Lu","year":"2008","journal-title":"AIDS Behav"},{"key":"10.1016\/j.rcsop.2022.100163_bb0140","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.sapharm.2009.06.005","article-title":"Development of a new scale to measure self-reported medication nonadherence","volume":"11","author":"Unni","year":"2015","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.rcsop.2022.100163_bb0145","article-title":"Comprehensive medication review service by embedded pharmacists in primary care: Innovations and impact","author":"Yoo","year":"2021","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.rcsop.2022.100163_bb0150","first-page":"1073","article-title":"Navigating the wild west of medication adherence reporting in specialty pharmacy","volume":"25","author":"Canfield","year":"2019","journal-title":"J Mdg Care Spec Pharm"},{"key":"10.1016\/j.rcsop.2022.100163_bb0155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","article-title":"Psychometric assessment of three newly developed implementation outcome measures","volume":"12","author":"Weiner","year":"2017","journal-title":"Implement Sci"},{"author":"PQA, Pharmacy Quality Alliance","key":"10.1016\/j.rcsop.2022.100163_bb0160"},{"key":"10.1016\/j.rcsop.2022.100163_bb0165","article-title":"Grounded theory research: a design framework for novice researchers","volume":"7","author":"Tie","year":"2019","journal-title":"SAGE Open Med"},{"issue":"suppl 3","key":"10.1016\/j.rcsop.2022.100163_bb0170","first-page":"S1","article-title":"NCCN task force report: oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.rcsop.2022.100163_bb0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JOP.2015.004002","article-title":"Extending the quality and safety agenda from parenteral to oral chemotherapy","volume":"11","author":"Krzyzanowska","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.rcsop.2022.100163_bb0180","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/S1470-2045(19)30656-4","article-title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review","volume":"20","author":"Mierzynska","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rcsop.2022.100163_bb0185","first-page":"1797","article-title":"The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices","volume":"25","author":"Salgado","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.rcsop.2022.100163_bb0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/jamaoncol.2017.0625","article-title":"Interventions to improve oral chemotherapy safety and quality: a systematic review","volume":"4","author":"Zerillo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rcsop.2022.100163_bb0195","article-title":"Impact of oral chemotherapy management program on capecitabine toxicity management","volume":"26","author":"Nhean","year":"2021","journal-title":"JCO Oncol Pract"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276622000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276622000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:27:54Z","timestamp":1757406474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276622000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"alternative-id":["S2667276622000622"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2022.100163","relation":{},"ISSN":["2667-2766"],"issn-type":[{"type":"print","value":"2667-2766"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA)","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2022.100163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100163"}}